Yanavich C, Pacheco AG, Cardoso SW, et al. - In HIV mono‐infected people, researchers assessed how accurate serological biomarkers for non‐alcoholic fatty liver disease (NAFLD) and advanced fibrosis (METAVIR‐F3F4) are. In all, 674 PROSPEC‐HIV study participants with blood sample tests and transient elastography (TE) conducted on the same day were eligible. Viral hepatitis co‐infection (n = 90), abusive alcohol intake (n = 61), incomplete data (n = 47) or unreliable TE (n = 39) were the exclusion criteria. In total, 437 patients [57% female, age = 44 (interquartile range: 35–52) years, BMI = 26.1 (23.4–29.3) kg/m², CD4 = 660 (427–901) cells/μL] were involved. Data revealed that the prevalence of NAFLD and advanced fibrosis were 38.2% and 10.5%, respectively. According to findings, biomarkers for NAFLD were accurate and those for fibrosis had high specificities and NPVs. For diagnosing NAFLD and excluding advanced liver fibrosis, these tests should be incorporated into HIV treatment.